Biogen Idec has submitted a biologics license application to the FDA for the use of recombinant factor IX Fc fusion protein as a treatment for hemophilia B. The company said a decision from the agency could come this year. Biogen Idec also said it is preparing to submit a similar application for a treatment for hemophilia A in the first three months of 2013.
Biogen Idec submits BLA for hemophilia B treatment
SmartBrief Job Listings for Health Care
|Senior Research Analyst||
America's Health Insurance Plans (AHIP)
|Manager, Regulatory Affairs||
|Washington DC, DC|
|Senior Counsel - FDA Regulatory Affairs||
|Director, Quality Assurance||
|Provider Relations Manager||
Breakthrough Behavioral, Inc.
|Redwood City, CA|